Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysis - Sacituzumab Govitecan in Pts With HR+/HER2- mBC"

705 views
June 7, 2023
Comments 0
Login to view comments. Click here to Login